Invention Grant
- Patent Title: Long-acting recombinant human follicle-stimulating hormone-Fc fusion protein
-
Application No.: US15033286Application Date: 2014-08-22
-
Publication No.: US10023624B2Publication Date: 2018-07-17
- Inventor: Yongmin Hou , Qiang Li , Maobo Wu , Sha Liao , Yujie Zhang , Zhenqi Xu
- Applicant: UnicoMed Pharma Co. Ltd.
- Applicant Address: CN Guangzhou, Guangdong
- Assignee: UnicoHealth Co. Ltd.
- Current Assignee: UnicoHealth Co. Ltd.
- Current Assignee Address: CN Guangzhou, Guangdong
- Agency: The Dobrusin Law Firm, PC
- Priority: CN201310529896 20131101
- International Application: PCT/CN2014/085010 WO 20140822
- International Announcement: WO2015/062349 WO 20150507
- Main IPC: C07K14/59
- IPC: C07K14/59 ; A61K38/00

Abstract:
Recombinant Fc fusion proteins of human follicle-stimulating hormone (hFSH) with in vivo biological activities comparable to those of human follicle-stimulating hormone are disclosed. A recombinant hFSH-Fc fusion protein comprises β subunit of hFSH (hFSH β), CTP, α subunit of hFSH (hFSH α), a flexible peptide linker, and human IgG2 Fc variant (vIgG2Fc). A method is also disclosed to make such fusion proteins at good expression levels. These recombinant hFSH-Fc fusion proteins of the present disclosure exhibit sufficient biological activities and prolonged plasma half-lives, leading to improved pharmacokinetics and pharmacodynamics. Thus, a lower dosage may be used and/or better or different therapeutic efficacies with less side effects may be achieved. A method for the application of the recombinant hFSH-Fc fusion proteins in the treatment and/or prevention of human infertility is also disclosed.
Public/Granted literature
- US20170174736A1 LONG-ACTING RECOMBINANT HUMAN FOLLICLE-STIMULATING HORMONE-FC FUSION PROTEIN Public/Granted day:2017-06-22
Information query